CTKB, US23285D1090

Cytek Biosciences stock gains 4.08 percent versus Tradegate close

Published on 10/20/2026 at 20:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Revenue rose 9.07 percent to USD 48.14 million. Cytek Biosciences stock costs EUR 4.85 on October 20, 2026, up 4.08 percent versus Tradegate.

Price and earnings at a glance

  • Cytek Biosciences stock gained 4.08 percent versus the Tradegate close on October 20, 2026.
  • Second-quarter revenue reached USD 48.14 million, 9.07 percent above the first quarter.
  • Cytek Biosciences stock costs EUR 4.85 at Lang & Schwarz on October 20, 2026 at 8:02 p.m. CEST.
  • The Nasdaq-listed company had a USD 709.1 million market capitalization as of October 20, 2026.
CTKB, US23285D1090, Illustration mit AI erstellt.

Cytek Biosciences stock gained 4.08 percent against the Tradegate close on October 20, 2026, giving the biotechnology company a stronger euro-market session than its recent Nasdaq performance. The move came as investors weighed the company's latest operating figures and its still-negative earnings profile. At Lang & Schwarz, it was EUR 4.85 on October 20, 2026 at 8:02 p.m. CEST, up 4.08 percent versus the Tradegate close of October 16, 2026 at EUR 4.66.

Revenue reached USD 48.14 million

Cytek reported USD 48.14 million in revenue for the second quarter of 2026, compared with USD 44.14 million in the first quarter. That 9.07 percent quarter-on-quarter increase was accompanied by a diluted loss of USD 0.09 per share. MarketBeat reported on October 6, 2026 that revenue exceeded analysts' USD 47.31 million estimate while earnings per share matched the USD 0.09 loss consensus.

Cytek remains below its yearly high

On the Nasdaq, Cytek was last at USD 5.46 on October 20, 2026 at 2:05 p.m. ET, with 287,680 shares traded. Its USD 3.31 to USD 6.21 52-week range places the Nasdaq price 12.08 percent below the high. The company had a USD 709.1 million market capitalization at the same point in the session.

The euro quotation and the Nasdaq quotation describe different venues and currencies. For German investors, the Lang & Schwarz price is the direct euro reference, while the Nasdaq quotation supplies the company's home-market context. The 4.08 percent gain against the Tradegate close therefore should not be combined with the Nasdaq's intraday change.

Losses remain part of the picture

Cytek posted a USD 12.16 million net loss in the second quarter of 2026, narrower than the USD 18.87 million loss in the first quarter. Operating margin improved from minus 42.00 percent to minus 24.00 percent over the same periods, but remained negative. Cash and cash equivalents rose from USD 65.67 million on March 31, 2026 to USD 73.85 million on June 30, 2026.

What the price move changes

The session gain places the euro quotation above its October 16 Tradegate close while leaving the primary-market price below the October 6 yearly high. The next investor test is whether revenue growth can continue while Cytek works toward lower operating losses.

Stock price and investor view

Cytek Biosciences combines a second-quarter revenue increase of 9.07 percent with a negative operating margin and a Nasdaq price 12.08 percent below its 52-week high. The further course of trading is shown by the continuously updated real-time quote of Cytek Biosciences stock.

Cytek Biosciences market data

  • Company: Cytek Biosciences, Inc.
  • ISIN: US23285D1090
  • Ticker: CTKB
  • Primary exchange: Nasdaq
  • Price Lang & Schwarz (as of October 20, 2026, 8:02 p.m. CEST): EUR 4.85
  • Change versus Tradegate close: plus 4.08 percent
  • Tradegate close (October 16, 2026): EUR 4.66
  • Market capitalization: USD 709.1 million (as of October 20, 2026)
  • 52-week range: USD 3.31-6.21 (as of October 20, 2026)
  • Sector / Industry: Health care / Health care equipment and supplies

Market context: Market report Nasdaq Composite.

More news and analyses on Cytek Biosciences stock

Disclaimer...
en | US23285D1090 | CTKB | boerse | 70377128 | bgmi